schliessen

Filtern

 

Bibliotheken

Vaccination of pigs against pseudorabies with highly attenuated vaccinia (NYVAC) recombinant viruses

Poxvirus recombinants, based on the highly attenuated NYVAC strain of vaccinia virus (Tartaglia et al., 1992), containing single gene inserts encoding the pseudorabies virus (PRV) gII, gIII, or gp50 glycoproteins were tested for their immunogenicity in pigs. Twenty-four pigs were randomly divided in... Full description

Journal Title: Veterinary microbiology 1993, Vol.38 (1), p.41-58
Main Author: Brockmeier, Susan L
Other Authors: Lager, Kelly M , Tartaglia, James , Riviere, Michel , Paoletti, Enzo , Mengeling, William L
Format: Electronic Article Electronic Article
Language: English
Subjects:
Pig
Publisher: Amsterdam: Elsevier B.V
ID: ISSN: 0378-1135
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: cdi_proquest_miscellaneous_76255142
title: Vaccination of pigs against pseudorabies with highly attenuated vaccinia (NYVAC) recombinant viruses
format: Article
creator:
  • Brockmeier, Susan L
  • Lager, Kelly M
  • Tartaglia, James
  • Riviere, Michel
  • Paoletti, Enzo
  • Mengeling, William L
subjects:
  • Animals
  • Antibodies, Viral - blood
  • Base Sequence
  • Biological and medical sciences
  • Body Temperature
  • Cell Line
  • Female
  • Fundamental and applied biological sciences. Psychology
  • Herpesvirus 1, Suid - genetics
  • Herpesvirus 1, Suid - immunology
  • Herpesvirus 1, Suid - isolation & purification
  • Male
  • Microbiology
  • Molecular Sequence Data
  • Nasal Mucosa - microbiology
  • Neutralization Tests - veterinary
  • Oligodeoxyribonucleotides - chemistry
  • Pharynx - microbiology
  • Pig
  • Polymerase Chain Reaction - veterinary
  • Pseudorabies - prevention & control
  • Pseudorabies virus
  • Radioimmunoprecipitation Assay - veterinary
  • Random Allocation
  • Swine
  • Swine Diseases - prevention & control
  • Trigeminal Ganglion - microbiology
  • Vaccination
  • Vaccination - veterinary
  • Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies
  • Vaccines, Synthetic - genetics
  • Vaccinia virus - genetics
  • Viral Vaccines - genetics
  • Virology
  • Virus Shedding
  • Weight Gain
ispartof: Veterinary microbiology, 1993, Vol.38 (1), p.41-58
description: Poxvirus recombinants, based on the highly attenuated NYVAC strain of vaccinia virus (Tartaglia et al., 1992), containing single gene inserts encoding the pseudorabies virus (PRV) gII, gIII, or gp50 glycoproteins were tested for their immunogenicity in pigs. Twenty-four pigs were randomly divided into six groups of four. Groups 1–3 were inoculated with 10 7 CCID 50 of NYVAC/PRV gII, NYVAC/PRV gIII, or NYVAC/PRV gp50, respectively, while groups 4 and 4 received the NYVAC parent virus or an inactivated PRV vaccine control, respectively. Group 6 represented the sham vaccinated control group. All inoculations were given by the intramuscular route on weeks 0 and 4. The candidate vaccines were shown to be safe with no local or systemic reactions. At 4 weeks following the second inoculation, all pigs were challenged by an oronasal administration of a virulent PRV strain. Pigs were monitored before and after challenge for clinical manifestations resulting from vaccination and challenge exposure, respectively. Sera were analyzed for PRV neutralizing activity. Virological analyses after challenge included assessment of virus shedding and the development of latent PRV infections. All but one animal developed latent PRV infection following challenge exposure; however, significant protection against PRV-induced signs was afforded by vaccination with either the NYVAC/PRV gp50 or NYVAC/PRV gII recombinant viruses, as well as with the inactivated PRV vaccine. The NYVAC/PRV gp50 also reduced overall virus shedding after challenge. The extent of protection against PRV-induced clinical signs, in general, was associated with the level of pre-challenge virus neutralizing activity.
language: eng
source:
identifier: ISSN: 0378-1135
fulltext: no_fulltext
issn:
  • 0378-1135
  • 1873-2542
url: Link


@attributes
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
RANK1.7198961
LOCALfalse
PrimoNMBib
record
control
sourceidproquest_cross
recordidTN_cdi_proquest_miscellaneous_76255142
sourceformatXML
sourcesystemPC
sourcerecordid76255142
originalsourceidFETCH-LOGICAL-c381t-5e2246df01337b72bf4e052eda0a8ee6116f913421b88d869ab97af9be6039b40
addsrcrecordideNp9kE1vEzEURS0EKmnhH4DkBULtYsBfM2NvkKqoEKQKNlCJlfVsv0mMJjPB9gT13zNpoixZvcU99-rpEPKGsw-c8eYjk62uOJf1tZE3hrFWVatnZMF1KytRK_GcLM7IS3KZ82_GmDINuyAXmgvdMLEg4QG8jwOUOA507OgurjOFNcQhF7rLOIUxgYuY6d9YNnQT15v-kUIpOExQMND9Uz8Cvf726-F2eUMT-nHr5smh0H1MU8b8irzooM_4-nSvyM_Pdz-Wq-r--5evy9v7ykvNS1WjEKoJHeNStq4VrlPIaoEBGGjEhvOmM1wqwZ3WQTcGnGmhMw4bJo1T7Iq8P-7u0vhnwlzsNmaPfQ8DjlO2bSPqmisxg-oI-jTmnLCzuxS3kB4tZ_Yg1x7M2YM5a6R9kmtXc-3taX9yWwzn0snmnL875ZA99F2Cwcd8xuS8Y_ThzU9HDGcX-4jJZh9x8BjiLK_YMMb___EPoCuWBA
sourcetypeAggregation Database
isCDItrue
recordtypearticle
pqid76255142
display
typearticle
titleVaccination of pigs against pseudorabies with highly attenuated vaccinia (NYVAC) recombinant viruses
creatorBrockmeier, Susan L ; Lager, Kelly M ; Tartaglia, James ; Riviere, Michel ; Paoletti, Enzo ; Mengeling, William L
creatorcontribBrockmeier, Susan L ; Lager, Kelly M ; Tartaglia, James ; Riviere, Michel ; Paoletti, Enzo ; Mengeling, William L
descriptionPoxvirus recombinants, based on the highly attenuated NYVAC strain of vaccinia virus (Tartaglia et al., 1992), containing single gene inserts encoding the pseudorabies virus (PRV) gII, gIII, or gp50 glycoproteins were tested for their immunogenicity in pigs. Twenty-four pigs were randomly divided into six groups of four. Groups 1–3 were inoculated with 10 7 CCID 50 of NYVAC/PRV gII, NYVAC/PRV gIII, or NYVAC/PRV gp50, respectively, while groups 4 and 4 received the NYVAC parent virus or an inactivated PRV vaccine control, respectively. Group 6 represented the sham vaccinated control group. All inoculations were given by the intramuscular route on weeks 0 and 4. The candidate vaccines were shown to be safe with no local or systemic reactions. At 4 weeks following the second inoculation, all pigs were challenged by an oronasal administration of a virulent PRV strain. Pigs were monitored before and after challenge for clinical manifestations resulting from vaccination and challenge exposure, respectively. Sera were analyzed for PRV neutralizing activity. Virological analyses after challenge included assessment of virus shedding and the development of latent PRV infections. All but one animal developed latent PRV infection following challenge exposure; however, significant protection against PRV-induced signs was afforded by vaccination with either the NYVAC/PRV gp50 or NYVAC/PRV gII recombinant viruses, as well as with the inactivated PRV vaccine. The NYVAC/PRV gp50 also reduced overall virus shedding after challenge. The extent of protection against PRV-induced clinical signs, in general, was associated with the level of pre-challenge virus neutralizing activity.
identifier
0ISSN: 0378-1135
1EISSN: 1873-2542
2DOI: 10.1016/0378-1135(93)90074-H
3PMID: 8128602
4CODEN: VMICDQ
languageeng
publisherAmsterdam: Elsevier B.V
subjectAnimals ; Antibodies, Viral - blood ; Base Sequence ; Biological and medical sciences ; Body Temperature ; Cell Line ; Female ; Fundamental and applied biological sciences. Psychology ; Herpesvirus 1, Suid - genetics ; Herpesvirus 1, Suid - immunology ; Herpesvirus 1, Suid - isolation & purification ; Male ; Microbiology ; Molecular Sequence Data ; Nasal Mucosa - microbiology ; Neutralization Tests - veterinary ; Oligodeoxyribonucleotides - chemistry ; Pharynx - microbiology ; Pig ; Polymerase Chain Reaction - veterinary ; Pseudorabies - prevention & control ; Pseudorabies virus ; Radioimmunoprecipitation Assay - veterinary ; Random Allocation ; Swine ; Swine Diseases - prevention & control ; Trigeminal Ganglion - microbiology ; Vaccination ; Vaccination - veterinary ; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies ; Vaccines, Synthetic - genetics ; Vaccinia virus - genetics ; Viral Vaccines - genetics ; Virology ; Virus Shedding ; Weight Gain
ispartofVeterinary microbiology, 1993, Vol.38 (1), p.41-58
rights
01993
11994 INIST-CNRS
lds50peer_reviewed
links
openurl$$Topenurl_article
thumbnail$$Usyndetics_thumb_exl
backlink
0$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=3900984$$DView record in Pascal Francis
1$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8128602$$D View this record in MEDLINE/PubMed
search
creatorcontrib
0Brockmeier, Susan L
1Lager, Kelly M
2Tartaglia, James
3Riviere, Michel
4Paoletti, Enzo
5Mengeling, William L
title
0Vaccination of pigs against pseudorabies with highly attenuated vaccinia (NYVAC) recombinant viruses
1Veterinary microbiology
addtitleVet Microbiol
descriptionPoxvirus recombinants, based on the highly attenuated NYVAC strain of vaccinia virus (Tartaglia et al., 1992), containing single gene inserts encoding the pseudorabies virus (PRV) gII, gIII, or gp50 glycoproteins were tested for their immunogenicity in pigs. Twenty-four pigs were randomly divided into six groups of four. Groups 1–3 were inoculated with 10 7 CCID 50 of NYVAC/PRV gII, NYVAC/PRV gIII, or NYVAC/PRV gp50, respectively, while groups 4 and 4 received the NYVAC parent virus or an inactivated PRV vaccine control, respectively. Group 6 represented the sham vaccinated control group. All inoculations were given by the intramuscular route on weeks 0 and 4. The candidate vaccines were shown to be safe with no local or systemic reactions. At 4 weeks following the second inoculation, all pigs were challenged by an oronasal administration of a virulent PRV strain. Pigs were monitored before and after challenge for clinical manifestations resulting from vaccination and challenge exposure, respectively. Sera were analyzed for PRV neutralizing activity. Virological analyses after challenge included assessment of virus shedding and the development of latent PRV infections. All but one animal developed latent PRV infection following challenge exposure; however, significant protection against PRV-induced signs was afforded by vaccination with either the NYVAC/PRV gp50 or NYVAC/PRV gII recombinant viruses, as well as with the inactivated PRV vaccine. The NYVAC/PRV gp50 also reduced overall virus shedding after challenge. The extent of protection against PRV-induced clinical signs, in general, was associated with the level of pre-challenge virus neutralizing activity.
subject
0Animals
1Antibodies, Viral - blood
2Base Sequence
3Biological and medical sciences
4Body Temperature
5Cell Line
6Female
7Fundamental and applied biological sciences. Psychology
8Herpesvirus 1, Suid - genetics
9Herpesvirus 1, Suid - immunology
10Herpesvirus 1, Suid - isolation & purification
11Male
12Microbiology
13Molecular Sequence Data
14Nasal Mucosa - microbiology
15Neutralization Tests - veterinary
16Oligodeoxyribonucleotides - chemistry
17Pharynx - microbiology
18Pig
19Polymerase Chain Reaction - veterinary
20Pseudorabies - prevention & control
21Pseudorabies virus
22Radioimmunoprecipitation Assay - veterinary
23Random Allocation
24Swine
25Swine Diseases - prevention & control
26Trigeminal Ganglion - microbiology
27Vaccination
28Vaccination - veterinary
29Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies
30Vaccines, Synthetic - genetics
31Vaccinia virus - genetics
32Viral Vaccines - genetics
33Virology
34Virus Shedding
35Weight Gain
issn
00378-1135
11873-2542
fulltextfalse
rsrctypearticle
creationdate1993
recordtypearticle
recordideNp9kE1vEzEURS0EKmnhH4DkBULtYsBfM2NvkKqoEKQKNlCJlfVsv0mMJjPB9gT13zNpoixZvcU99-rpEPKGsw-c8eYjk62uOJf1tZE3hrFWVatnZMF1KytRK_GcLM7IS3KZ82_GmDINuyAXmgvdMLEg4QG8jwOUOA507OgurjOFNcQhF7rLOIUxgYuY6d9YNnQT15v-kUIpOExQMND9Uz8Cvf726-F2eUMT-nHr5smh0H1MU8b8irzooM_4-nSvyM_Pdz-Wq-r--5evy9v7ykvNS1WjEKoJHeNStq4VrlPIaoEBGGjEhvOmM1wqwZ3WQTcGnGmhMw4bJo1T7Iq8P-7u0vhnwlzsNmaPfQ8DjlO2bSPqmisxg-oI-jTmnLCzuxS3kB4tZ_Yg1x7M2YM5a6R9kmtXc-3taX9yWwzn0snmnL875ZA99F2Cwcd8xuS8Y_ThzU9HDGcX-4jJZh9x8BjiLK_YMMb___EPoCuWBA
startdate1993
enddate1993
creator
0Brockmeier, Susan L
1Lager, Kelly M
2Tartaglia, James
3Riviere, Michel
4Paoletti, Enzo
5Mengeling, William L
general
0Elsevier B.V
1Elsevier Science
scope
0IQODW
1CGR
2CUY
3CVF
4ECM
5EIF
6NPM
7AAYXX
8CITATION
97X8
sort
creationdate1993
titleVaccination of pigs against pseudorabies with highly attenuated vaccinia (NYVAC) recombinant viruses
authorBrockmeier, Susan L ; Lager, Kelly M ; Tartaglia, James ; Riviere, Michel ; Paoletti, Enzo ; Mengeling, William L
facets
frbrtype5
frbrgroupidcdi_FETCH-LOGICAL-c381t-5e2246df01337b72bf4e052eda0a8ee6116f913421b88d869ab97af9be6039b40
rsrctypearticles
prefilterarticles
languageeng
creationdate1993
topic
0Animals
1Antibodies, Viral - blood
2Base Sequence
3Biological and medical sciences
4Body Temperature
5Cell Line
6Female
7Fundamental and applied biological sciences. Psychology
8Herpesvirus 1, Suid - genetics
9Herpesvirus 1, Suid - immunology
10Herpesvirus 1, Suid - isolation & purification
11Male
12Microbiology
13Molecular Sequence Data
14Nasal Mucosa - microbiology
15Neutralization Tests - veterinary
16Oligodeoxyribonucleotides - chemistry
17Pharynx - microbiology
18Pig
19Polymerase Chain Reaction - veterinary
20Pseudorabies - prevention & control
21Pseudorabies virus
22Radioimmunoprecipitation Assay - veterinary
23Random Allocation
24Swine
25Swine Diseases - prevention & control
26Trigeminal Ganglion - microbiology
27Vaccination
28Vaccination - veterinary
29Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies
30Vaccines, Synthetic - genetics
31Vaccinia virus - genetics
32Viral Vaccines - genetics
33Virology
34Virus Shedding
35Weight Gain
toplevelpeer_reviewed
creatorcontrib
0Brockmeier, Susan L
1Lager, Kelly M
2Tartaglia, James
3Riviere, Michel
4Paoletti, Enzo
5Mengeling, William L
collection
0Pascal-Francis
1Medline
2MEDLINE
3MEDLINE (Ovid)
4MEDLINE
5MEDLINE
6PubMed
7CrossRef
8MEDLINE - Academic
jtitleVeterinary microbiology
delivery
delcategoryRemote Search Resource
fulltextno_fulltext
addata
au
0Brockmeier, Susan L
1Lager, Kelly M
2Tartaglia, James
3Riviere, Michel
4Paoletti, Enzo
5Mengeling, William L
formatjournal
genrearticle
ristypeJOUR
atitleVaccination of pigs against pseudorabies with highly attenuated vaccinia (NYVAC) recombinant viruses
jtitleVeterinary microbiology
addtitleVet Microbiol
date1993
risdate1993
volume38
issue1
spage41
epage58
pages41-58
issn0378-1135
eissn1873-2542
codenVMICDQ
abstractPoxvirus recombinants, based on the highly attenuated NYVAC strain of vaccinia virus (Tartaglia et al., 1992), containing single gene inserts encoding the pseudorabies virus (PRV) gII, gIII, or gp50 glycoproteins were tested for their immunogenicity in pigs. Twenty-four pigs were randomly divided into six groups of four. Groups 1–3 were inoculated with 10 7 CCID 50 of NYVAC/PRV gII, NYVAC/PRV gIII, or NYVAC/PRV gp50, respectively, while groups 4 and 4 received the NYVAC parent virus or an inactivated PRV vaccine control, respectively. Group 6 represented the sham vaccinated control group. All inoculations were given by the intramuscular route on weeks 0 and 4. The candidate vaccines were shown to be safe with no local or systemic reactions. At 4 weeks following the second inoculation, all pigs were challenged by an oronasal administration of a virulent PRV strain. Pigs were monitored before and after challenge for clinical manifestations resulting from vaccination and challenge exposure, respectively. Sera were analyzed for PRV neutralizing activity. Virological analyses after challenge included assessment of virus shedding and the development of latent PRV infections. All but one animal developed latent PRV infection following challenge exposure; however, significant protection against PRV-induced signs was afforded by vaccination with either the NYVAC/PRV gp50 or NYVAC/PRV gII recombinant viruses, as well as with the inactivated PRV vaccine. The NYVAC/PRV gp50 also reduced overall virus shedding after challenge. The extent of protection against PRV-induced clinical signs, in general, was associated with the level of pre-challenge virus neutralizing activity.
copAmsterdam
pubElsevier B.V
pmid8128602
doi10.1016/0378-1135(93)90074-H